PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient

Blesa, Joan Manel Gasent; Candel, Vicente Alberola

doi:10.1159/000264612

Cited by 7 publications

(3 citation statements)

References 10 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While bevacizumab (VEGF-A monoclonal antibody) has been approved by the U.S. Food and Drug Administration in the treatment of glioblastoma, colorectal cancer, renal cell carcinoma, and other cancer types, some small studies have shown promise in reducing vestibular schwannoma tumor size as well as associated symptomatic improvement. [ 111 130 ] Nevertheless, our understanding of the exact biology of this benign tumor is incomplete and thus warrants further research to elucidate the underlying aberrant molecular signaling. Through a better understanding of the altered signaling pathways in pathology, new therapeutic targets can be identified to improve the outcome of patients with neurosurgical pathologies.…”

Section: Aberrant Signaling In Neurovascular Pathologymentioning

confidence: 99%

Neurovascular patterning cues and implications for central and peripheral neurological disease

et al. 2017

View full text Add to dashboard Cite

The highly branched nervous and vascular systems run along parallel trajectories throughout the human body. This stereotyped pattern of branching shared by the nervous and vascular systems stems from a common reliance on specific cues critical to both neurogenesis and angiogenesis. Continually emerging evidence supports the notion of later-evolving vascular networks co-opting neural molecular mechanisms to ensure close proximity and adequate delivery of oxygen and nutrients to nervous tissue. As our understanding of these biologic pathways and their phenotypic manifestations continues to advance, identification of where pathways go awry will provide critical insight into central and peripheral nervous system pathology.

show abstract

Section: Aberrant Signaling In Neurovascular Pathologymentioning

confidence: 99%

Neurovascular patterning cues and implications for central and peripheral neurological disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Moreover, an in vitro study performed using LNCaP PCa cells suggested that fulvestrant could inhibit AR transcripts, decreasing the response to androgens [ 193 ]. Based on these premises, the drug was tested in clinical trials in men affected by androgen-independent PCa, with contrasting results, animating the debate about its real benefits [ 195 , 195 , 217 , 222 , 223 ]. Interestingly, encouraging data came from the combinatorial use of fulvestrant and immunotherapy, although in the context of breast cancer [ 224 , 225 , 226 , 227 ].…”

Section: Molecules Targeting Nuclear Estrogen Receptorsmentioning

confidence: 99%

Nuclear Estrogen Receptors in Prostate Cancer: From Genes to Function

Belluti,

Imbriano,

Casarini

2023

Cancers

View full text Add to dashboard Cite

Estrogens are almost ubiquitous steroid hormones that are essential for development, metabolism, and reproduction. They exert both genomic and non-genomic action through two nuclear receptors (ERα and ERβ), which are transcription factors with disregulated functions and/or expression in pathological processes. In the 1990s, the discovery of an additional membrane estrogen G-protein-coupled receptor augmented the complexity of this picture. Increasing evidence elucidating the specific molecular mechanisms of action and opposing effects of ERα and Erβ was reported in the context of prostate cancer treatment, where these issues are increasingly investigated. Although new approaches improved the efficacy of clinical therapies thanks to the development of new molecules targeting specifically estrogen receptors and used in combination with immunotherapy, more efforts are needed to overcome the main drawbacks, and resistance events will be a challenge in the coming years. This review summarizes the state-of-the-art on ERα and ERβ mechanisms of action in prostate cancer and promising future therapies.

show abstract

“…Transduction pathways should probably be considered when testing AR antagonists: their inhibition may restore sensitivity to androgen antagonists. Anothertherapeuticpathwaycouldbeinterestingtoexplore: J.M.GasentBlesaandV.AlberolaCandelreportinthisissue of OnkOlOgie on the case of a metastatic prostate cancer patient successfully treated with fulvestrant [1]. This 79 year-old patient with initially metastatic prostate cancer first received completeandrogenblockade(CAB)andthenhigh-dosebicalutamide because of intolerance to LH-RH agonist.…”

mentioning

confidence: 99%